INVESTOR INTELLIGENCE

The Daily Briefing

Biotech news, drug catalysts, and the market moves that matter.

LEAD STORY
RESEARCH

PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026

FirstWord Pharma Nov 20
THE NEWSROOM

Latest Intelligence

THE NEWSLETTER

The Oracle Report

Daily biotech intelligence on clinical catalysts, regulatory decisions, licensing deals, and investment implications.

Join The Oracle Report (opens in a new tab)